iScience (Dec 2023)
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
- Helen Ratcliffe,
- Karen S. Tiley,
- Stephanie Longet,
- Claire Tonry,
- Cathal Roarty,
- Chris Watson,
- Gayatri Amirthalingam,
- Iason Vichos,
- Ella Morey,
- Naomi L. Douglas,
- Spyridoula Marinou,
- Emma Plested,
- Parvinder K. Aley,
- Eva Galiza,
- Saul N. Faust,
- Stephen Hughes,
- Clare Murray,
- Marion R. Roderick,
- Fiona Shackley,
- Sam Oddie,
- Tim W.R. Lee,
- David P.J. Turner,
- Mala Raman,
- Stephen Owens,
- Paul J. Turner,
- Helen Cockerill,
- Jamie Lopez Bernal,
- Samreen Ijaz,
- John Poh,
- Justin Shute,
- Ezra Linley,
- Ray Borrow,
- Katja Hoschler,
- Kevin E. Brown,
- Miles W. Carroll,
- Paul Klenerman,
- Susanna J. Dunachie,
- Mary Ramsay,
- Merryn Voysey,
- Thomas Waterfield,
- Matthew D. Snape
Affiliations
- Helen Ratcliffe
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK; Corresponding author
- Karen S. Tiley
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK
- Stephanie Longet
- Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- Claire Tonry
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast- School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK
- Cathal Roarty
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast- School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK
- Chris Watson
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast- School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK
- Gayatri Amirthalingam
- UK Health Security Agency
- Iason Vichos
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK
- Ella Morey
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK
- Naomi L. Douglas
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK
- Spyridoula Marinou
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK
- Emma Plested
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK
- Parvinder K. Aley
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK
- Eva Galiza
- St Georges Hospital NHS Foundation Trust
- Saul N. Faust
- NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust and Faculty of Medicine and Institute of Life Sciences, University of Southampton; National Immunisation Schedule Evaluation Consortium
- Stephen Hughes
- Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester, UK
- Clare Murray
- Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester, UK; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, Manchester, UK
- Marion R. Roderick
- University Hospitals Bristol NHS Foundation Trust
- Fiona Shackley
- Sheffield Children’s Hospital NHS Trust
- Sam Oddie
- Bradford Teaching Hospitals NHS Foundation Trust
- Tim W.R. Lee
- Leeds Teaching Hospitals NHS Trust
- David P.J. Turner
- School of Life Sciences, University of Nottingham; Nottingham University Hospitals NHS Trust
- Mala Raman
- University Hospitals Plymouth NHS Trust
- Stephen Owens
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
- Paul J. Turner
- National Heart & Lung Institute, Imperial College London
- Helen Cockerill
- National Heart & Lung Institute, Imperial College London
- Jamie Lopez Bernal
- UK Health Security Agency
- Samreen Ijaz
- UK Health Security Agency
- John Poh
- UK Health Security Agency
- Justin Shute
- UK Health Security Agency
- Ezra Linley
- UK Health Security Agency
- Ray Borrow
- UK Health Security Agency
- Katja Hoschler
- UK Health Security Agency
- Kevin E. Brown
- UK Health Security Agency
- Miles W. Carroll
- Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
- Paul Klenerman
- Translational Gastroenterology Unit, University of Oxford, Oxford, UK; National Institute for Health Research (NIHR) Oxford BRC
- Susanna J. Dunachie
- National Institute for Health Research (NIHR) Oxford BRC; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
- Mary Ramsay
- UK Health Security Agency
- Merryn Voysey
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK
- Thomas Waterfield
- Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast- School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK
- Matthew D. Snape
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK; National Immunisation Schedule Evaluation Consortium; West Suffolk NHS Foundation Trust
- Journal volume & issue
-
Vol. 26,
no. 12
p. 108500
Abstract
Summary: SARS-CoV-2 infections in children are generally asymptomatic or mild and rarely progress to severe disease and hospitalization. Why this is so remains unclear. Here we explore the potential for protection due to pre-existing cross-reactive seasonal coronavirus antibodies and compare the rate of antibody decline for nucleocapsid and spike protein in serum and oral fluid against SARS-CoV-2 within the pediatric population. No differences in seasonal coronaviruses antibody concentrations were found at baseline between cases and controls, suggesting no protective effect from pre-existing immunity against seasonal coronaviruses. Antibodies against seasonal betacoronaviruses were boosted in response to SARS-CoV-2 infection. In serum, anti-nucleocapsid antibodies fell below the threshold of positivity more quickly than anti-spike protein antibodies. These findings add to our understanding of protection against infection with SARS-CoV-2 within the pediatric population, which is important when considering pediatric SARS-CoV-2 immunization policies.
